Adrabetadex for Niemann-Pick disease type C
The FDA is expected to decide on Adrabetadex for Niemann-Pick disease type C by November 17, 2026, under a NDA from Beren Therapeutics.
What is being decided
Beren Therapeutics has a NDA under FDA review for Adrabetadex in Niemann-Pick disease type C. Review extended after an FDA information request, the latest turn in a development saga stretching back years.
Who this decision matters to
Niemann-Pick Disease Type C (NPC) is a rare, progressive lysosomal lipid storage disorder caused by mutations in the NPC1 or NPC2 genes, which encode proteins critical for cholesterol and lipid trafficking. This leads to accumulation of unesterified cholesterol and other lipids in lysosomes, particularly in the nervous system and liver, causing progressive neurological deterioration and hepatosplenomegaly.
Prevalence: Approximately 1 per 100,000 to 1 per 150,000 live births; higher in certain populations. See our full Niemann-Pick Disease Type C page for current treatments, recruiting trials, and community resources.
What each outcome would mean
An approval starts a second race rather than ending the first one: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. Our guide to the 90 days after a rare disease approval explains the timeline and the moves families can make on day 1.
A complete response letter would mean the FDA declined to approve in the application's current form. CRLs are often about manufacturing or data presentation rather than efficacy, and resubmission is common. Either way, this page updates with the outcome and what it means.
Where Niemann-Pick Disease Type C treatment stands today
Research in Niemann-Pick Type C is advancing through multiple approaches to slow the devastating neurological progression that characterizes this condition. Miglustat and other iminosugars work by reducing substrate accumulation, while substrate reduction therapies and cyclodextrin derivatives offer additional mechanisms. Gene therapy and cell-based therapies represent exciting emerging approaches. Trials measure treatment effects through standardized neurological rating scales, gait assessment, cognitive testing, eye movement abnormalities, and brain imaging, along with biochemical markers reflecting disease burden. Early intervention before or very early in symptom appearance shows the most promise. Genetic confirmation through NPC1/2 testing helps guide treatment selection. Family members who have inherited the same mutation benefit from screening and early intervention discussion before symptoms develop. Biomarker monitoring helps track disease progression and treatment response.
Meanwhile, 7 Niemann-Pick Disease Type C trials are recruiting
Whatever the FDA decides here, research on Niemann-Pick Disease Type C does not stop. A few currently enrolling studies, US sites first:
Get notified when new niemann-pick-disease-type-c trials open or existing trials change status, add sites, or update eligibility.
Frequently asked questions
When will the FDA decide on Adrabetadex?
The FDA's target decision date (PDUFA date) for Adrabetadex in Niemann-Pick disease type C is November 17, 2026, disclosed by Beren Therapeutics. The agency can act before this date and occasionally runs past it.
What is Adrabetadex being reviewed for?
Beren Therapeutics submitted a NDA for Adrabetadex in Niemann-Pick disease type C. Review extended after an FDA information request, the latest turn in a development saga stretching back years.
What happens after the Adrabetadex decision?
If approved, availability is not immediate: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. If the FDA issues a complete response letter, the application was not approved in its current form; CRLs are often about manufacturing or data presentation rather than efficacy, and sponsors frequently resubmit. This page updates with the outcome either way.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from Fierce Biotech report. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified weekly.